Comparison of secretin and vasoactive intestinal peptide on pancreatic secretion in dogs.

Konturek SJ, Thor P, Dembinski A, Krol R

Gastroenterology1 Jun 1975Cited by 30 (Europe PMC)

PMID1132634DOI10.1016/s0016-5085(75)80141-7PepBankPUB-01132634

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In dogs with gastric and pancreatic fistulas, the maximal bicarbonate response to VIP was about 17% of that to secretin.
In plain wordsIn dogs, VIP produced much less pancreatic bicarbonate than secretin.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseMaximal pancreatic bicarbonate response relative to secretin
Study
dogn: not reported in source
chronic gastric and pancreatic fistula dogs
Comparator
Secretin
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Measurements
Maximal bicarbonate response relative to secretin
≈ 17%
VIP
Source sentences
Summary
Dose-response analysis showed that maximal bicarbonate response to VIP was about 17% of that to secretin.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive inhibitory peptide (VIP) and secretin were compared in regard to the stimulation of pancreatic bicarbonate secretion and the augmentation of pancreatic response to caerulein or a peptone meal in chronic gastric and pancreatic fistula dogs.
Report a problemFND-0113263401
02AnimalAnimal study (in vivo)Efficacy outcome
In dogs, VIP was a potent inhibitor of secretin-induced pancreatic secretion.
In plain wordsIn dogs, VIP reduced pancreatic secretion caused by secretin compared with secretin alone.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseSecretin-induced pancreatic secretion with VIP
Study
dogn: not reported in source
chronic gastric and pancreatic fistula dogs
Comparator
Secretin alone
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The interactions of these two peptides showed that VIP is a potent inhibitor of secretin-induced pancreatic secretion.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive inhibitory peptide (VIP) and secretin were compared in regard to the stimulation of pancreatic bicarbonate secretion and the augmentation of pancreatic response to caerulein or a peptone meal in chronic gastric and pancreatic fistula dogs.
Report a problemFND-0113263404
03AnimalAnimal study (in vivo)Mechanism
In dogs, dose-response curves to secretin alone and secretin plus VIP showed typical competitive inhibition, which indicates a common receptor site for VIP and secretin.
In plain wordsIn dogs, dose-response data suggest VIP and secretin act at the same receptor site.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableCompetitive inhibition of secretin by VIP
Study
dogn: not reported in source
chronic gastric and pancreatic fistula dogs
Comparator
Secretin alone
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
From the dose-response curves to secretin alone and secretin plus VIP, Michaelis-Menten analysis showed typical competitive inhibition, which indicates that VIP and secretin share a common receptor site.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive inhibitory peptide (VIP) and secretin were compared in regard to the stimulation of pancreatic bicarbonate secretion and the augmentation of pancreatic response to caerulein or a peptone meal in chronic gastric and pancreatic fistula dogs.
Report a problemFND-0113263405

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

04AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Efficacy outcome
In dogs, caerulein potentiated the pancreatic bicarbonate response to VIP in a manner similar to secretin.
In plain wordsIn dogs, caerulein increased the pancreas bicarbonate response to VIP compared with VIP alone.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePotentiation of VIP-induced bicarbonate response by caerulein
Study
dogn: not reported in source
chronic gastric and pancreatic fistula dogs
Comparator
VIP alone
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Both caerulein and endogenous cholecystokinin, released by a peptone meal, clearly potentiated pancreatic bicarbonate response to VIP in a manner similar to secretin.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive inhibitory peptide (VIP) and secretin were compared in regard to the stimulation of pancreatic bicarbonate secretion and the augmentation of pancreatic response to caerulein or a peptone meal in chronic gastric and pancreatic fistula dogs.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0113263402
05AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Efficacy outcome
In dogs, endogenous cholecystokinin released by a peptone meal potentiated the pancreatic bicarbonate response to VIP in a manner similar to secretin.
In plain wordsIn dogs, a meal that releases the body's own cholecystokinin increased the pancreas response to VIP compared with VIP alone.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePotentiation of VIP-induced bicarbonate response by peptone meal
Study
dogn: not reported in source
chronic gastric and pancreatic fistula dogs
Comparator
VIP alone
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
Both caerulein and endogenous cholecystokinin, released by a peptone meal, clearly potentiated pancreatic bicarbonate response to VIP in a manner similar to secretin.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive inhibitory peptide (VIP) and secretin were compared in regard to the stimulation of pancreatic bicarbonate secretion and the augmentation of pancreatic response to caerulein or a peptone meal in chronic gastric and pancreatic fistula dogs.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0113263403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.